UCB sues Sun over knockoff seizure drug; Indian pharmas struggle for beachhead in Japan;

gavel and books

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce

@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

> Belgium's UCB sued Sun Pharmaceutical Industries over the latter's planned generic version of the seizure drug Vimpat. Report (reg. req.)

> Indian drugmakers are struggling to make a dent in Japan's generics market, the world's second largest, with only a few so far able to establish a presence there. Report

> The FDA expanded the age range for Novartis' ($NVS) meningococcal vaccine Menveo, allowing the drugmaker to offer one vaccine to infants, children and adolescents. Report

> Sanofi's ($SNY) Indian unit inked a deal with the country's largest wind-turbine maker for a 2.1 megawatt off-site windmill installation. Report

> The FDA gave its blessing to Bayer's animal health drugs ProstaMate and OvaCyst, used to manage reproduction. Report

> The FDA warned that acetaminophen can cause rare but serious skin diseases. Report

> Despite new price cuts in effect in India, some pharmacies are selling multinational drugmakers' products at the old prices. Report

> India's Piramal plans to raise about $61.57 million by issuing 11.75% commercial paper. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev

@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce

@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce

@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from FierceDrugDelivery | Follow @MichaelGFierce

> M&A report: Theragenics agrees to $68M buyout. Story

> Stryker CEO: So far, so good after one year. Item

Biotech News

@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech

@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce

@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce

> BioMotiv garners $46M for early-stage licensing deals, R&D work. Article

> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report

> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News

CRO News

> Charles River boosts sales as charges drag profits. Article

> INC expands in Japan as local market soars. Story

> Clinipace reaches into the north with CRO partnership. Item

> Quintiles posts flat revenue as charges swallow profits. Report

> Covance swings to profit despite tough early-phase market. More

> KKR buying RPS, planning to merge it with PRA. Article

Biotech IT News

> China pharma R&D drives expanded use of Medidata software. News

> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More

> Accelrys to ax 80 jobs after drop in quarterly profits. News

> Battle against breast cancer goes open source. Story

> Ex-Yahoo CEO backs genomics big data startup Bina. Article

And Finally... Antibiotic resistance in hospital-acquired illness is much greater than the Centers for Disease Control and Prevention (CDC) previously thought. Report


Suggested Articles

The FDA is reportedly mulling a warning letter for an Eli Lilly site where its COVID-19 antibody would be produced.

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.